Abstract:Invading pathogen nucleic acids are recognized and bound by cytoplasmic (retinoic acid-inducible gene I [RIG-I]like) and membrane-bound (Toll-like) pattern recognition receptors to activate innate immune signaling. Modified nucleotides, when present in RNA molecules, diminish the magnitude of these signaling responses. However, mechanisms explaining the blunted signaling have not been elucidated. In this study, we used several independent biological assays, including inhibition of virus replication, RIG-I: RNA binding assays, and limited trypsin digestion of RIG-I: RNA complexes, to begin to understand how RNAs containing modified nucleotides avoid or suppress innate immune signaling. The experiments were based on a model innate immune activating RNA molecule, the polyU/UC RNA domain of hepatitis C virus, which was transcribed in vitro with canonical nucleotides or with one of eight modified nucleotides. The approach revealed signature assay responses associated with individual modified nucleotides or classes of modified nucleotides. For example, while both N-6-methyladenosine (m6A) and pseudouridine nucleotides correlate with diminished signaling, RNA containing m6A modifications bound RIG-I poorly, while RNA containing pseudouridine bound RIG-I with high affinity but failed to trigger the canonical RIG-I conformational changes associated with robust signaling. These data advance understanding of RNA-mediated innate immune signaling, with additional relevance for applying nucleotide modifications to RNA therapeutics.IMPORTANCE The innate immune system provides the first response to virus infections and must distinguish between host and pathogen nucleic acids to mount a protective immune response without activating autoimmune responses. While the presence of nucleotide modifications in RNA is known to correlate with diminished innate immune signaling, the underlying mechanisms have not been explored. The data reported here are important for defining mechanistic details to explain signaling suppression by RNAs containing modified nucleotides. The results suggest that RNAs containing modified nucleotides interrupt signaling at early steps of the RIG-I-like innate immune activation pathway and also that nucleotide modifications with similar chemical structures can be organized into classes that suppress or evade innate immune signaling steps. These data contribute to defining the molecular basis for innate immune signaling suppression by RNAs containing modified nucleotides. The results have important implications for designing therapeutic RNAs that evade innate immune detection.

RIG-I recognizes metabolite-capped RNAs as signaling ligands

Structural Basis for M7g Recognition and 2′-O-methyl Discrimination in Capped RNAs by the Innate Immune Receptor RIG-I

Structural and Mechanistic Basis for Self Versus Non‐self RNA Discrimination by the Innate Immune Receptor RIG‐I

A ribosomal RNA fragment with 2′,3′-cyclic phosphate and GTP-binding activity acts as RIG-I ligand

Structural and Functional Insights into 5′-Ppp RNA Pattern Recognition by the Innate Immune Receptor RIG-I

RNAs Containing Modified Nucleotides Fail to Trigger RIG-I Conformational Changes for Innate Immune Signaling

The structural basis of 5' triphosphate double-stranded RNA recognition by RIG-I C-terminal domain.

RIG-I Uses an ATPase-Powered Translocation-Throttling Mechanism for Kinetic Proofreading of RNAs and Oligomerization

Reconstitution of the RIG-I Pathway Reveals a Signaling Role of Unanchored Polyubiquitin Chains in Innate Immunity

The molecular language of RNA 5' ends: guardians of RNA identity and immunity

Master sensors of pathogenic RNA - RIG-I like receptors

RIG-I in RNA virus recognition

Agonist and Antagonist Recognition by Rig-I, A Cytoplasmic Innate Immunity Receptor

Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5

Actin cytoskeleton remodeling primes RIG-I-like receptor activation

An MST-based assay reveals new binding preferences of IFIT1 for canonically and non-canonically capped RNAs

Influenza A virus transcription generates capped cRNAs that activate RIG-I

The RIG-I-like Receptor LGP2 Recognizes the Termini of Double-stranded RNA

Crystal Structure Of Rig-I C-Terminal Domain Bound To Blunt-Ended Double-Strand Rna Without 5' Triphosphate

Structural and biochemical studies of RIG-I antiviral signaling

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses